Anxiety, depression, and psychosis in Parkinson's disease: Unmet needs and treatment challenges

Neurologic Clinics

Volumn 22, Issue 3 SUPPL., 2004, Pages

  Chen, Jack J ^a,b,c,d,e,f  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c ASTRAZENECA   (United Kingdom)

^d Bertek   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Teva Neuroscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE; BROMAZEPAM; BUSPIRONE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; QUETIAPINE; RASAGILINE; S ADENOSYLMETHIONINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

AGITATION; AGRANULOCYTOSIS; ALERTNESS; ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; GLUCOSE INTOLERANCE; HALLUCINATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSALIVATION; HYPERTENSION; HYPERTENSIVE CRISIS; HYPONATREMIA; HYPOTENSION; INSOMNIA; INTERVIEW; LABORATORY TEST; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MYOCARDITIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY; RATING SCALE; REM SLEEP; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STANDING; SWEATING; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT CONTRAINDICATION; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA; COMORBIDITY; CROSS-SECTIONAL STUDY; DRUG INTERACTION; HEALTH SERVICE; STATISTICS;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PARKINSON DISEASE;

EID: 14244258615     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2004.06.008     Document Type: Review

References (224)

1. I.H. Richard, R.B. Schiffer, and R. Kurlan Anxiety and Parkinson's disease J Neuropsychiatry Clin Neurosci 8 1996 383 392
2. E. Tandberg, J.P. Larsen, D. Aarsland, and J.L. Cummings The occurrence of depression in Parkinson's disease: a community based study Arch Neurol 53 1996 175 179
3. G. Fénelon, F. Mahieux, R. Huon, and M. Ziéflwe Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors Brain 123 2000 733 745
4. D. Aarsland, J.P. Larsen, J.L. Cummins, and K. Laake Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study Arch Neurol 56 1999 595 601
5. D. Weintraub, P.J. Moberg, J.E. Duda, I.R. Katz, and M.B. Stern Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease J Am Geriatr Soc 52 2004 784 788
6. J.L. Mathias Neurobehavioral functioning of persons with Parkinson's disease Appl Neuropsychol 10 2003 57 68
7. S. Norman, A.I. Troster, J.A. Fields, and R. Brooks Effects of depression and Parkinson's disease on cognitive functioning J Neuropsychiatry Clin Neurosci 14 2002 31 36
8. E. Cubo, B. Bernard, S. Leurgans, and R. Raman Cognitive and motor function in patients with Parkinson's disease with and without depression Clin Neuropharmacol 23 2000 331 334
9. C.Y. Liu, S.J. Wang, J.L. Fuh, C.H. Lin, Y.Y. Yang, and H.C. Liu The correlation of depression with functional activity in Parkinson's disease J Neurol 244 1997 493 498
10. L.C. Routh, J.L. Black, and J.E. Ahlskog Parkinson's disease complicated by anxiety Mayo Clin Proc 62 1987 733 735
11. Global Parkinson's Disease Survey (GPDS) Steering Committee Factors impacting on quality of life in Parkinson's disease: results from an international survey Mov Disord 17 2002 60 67
12. A.M. Kuopio, R.J. Marttila, H. Helenius, M. Toivonen, and U.K. Rinne The quality of life in Parkinson's disease Mov Disord 15 2000 216 223
13. A. Schrag, M. Jahanshahi, and N. Quinn What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 69 2000 308 312
14. A.J. Ostheimer An essay on the shaking palsy, by James Parkinson, MD, Member of the Royal College of Surgeons Arch Neurol Psychiatry 7 1922 681 710
15. L.M. Shulman, R.L. Taback, A.A. Rabinstein, and W.J. Weiner Non-recognition of depression and other non-motor symptoms in Parkinson's disease Parkinsonism Relat Dis 8 2002 193 197
16. S.E. Starkstein, R.G. Robinson, R. Leiguardia, and T.J. Preziosi Anxiety and depression in Parkinson's disease Behav Neurol 6 1993 151 154
17. M.B. Stein, I.J. Heuser, J.L. Juncos, and T.W. Uhde Anxiety disorders in patients with Parkinson's disease Am J Psychiatry 147 1990 217 220
18. M.A. Menza, D.E. Robertson-Hoffman, and A.S. Bonapace Parkinson's disease and anxiety: comorbidity with depression Biol Psychiatry 34 1993 465 470
19. A. Nuti, R. Ceravolo, A. Piccinni, G. Dell'Agnello, G. Bellini, and G. Gambaccini Psychiatric comorbidity in a population of Parkinson's disease patients Eur J Neurol 11 2004 315 320
20. A. Vazquez, F.J. Jimenez-Jimenez, P. Garcia-Ruiz, and D. Garcia-Urra "Panic attacks" in Parkinson's disease: a long-term complication of levodopa therapy Acta Neurol Scand 87 1993 14 18
21. A.L. Adkin, J.S. Frank, and M.S. Jog Fear of falling and postural control in Parkinson's disease Mov Disord 18 2003 496 502
22. L.M. Shulman, C. Singer, J.A. Bean, and W.J. Weiner Internal tremor in patients with Parkinson's disease Mov Disord 11 1996 3 7
23. B.A. Racette, J.M. Hartlein, T. Hershey, J.W. Mink, J.S. Perlmutter, and K.J. Black Clinical features and comorbidity of mood fluctuations in Parkinson's disease J Neuropsychiatry Clin Neurosci 14 2002 438 442
24. T. Witjas, E. Kaphan, J.P. Azulay, O. Blin, M. Ceccaldi, and J. Pouget Nonmotor fluctuations in Parkinson's disease: frequent and disabling Neurology 59 2002 408 413
25. D.L. Friedenberg, and J.L. Cummings Parkinson's disease, depression, and the on-off phenomenon Psychosomatics 30 1989 94 99
26. E.C. Lauterbach, A. Freeman, and R.L. Vogel Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease Cog Behav Neurol 16 2003 225 233
27. L.K. Kerenyi, G.A. Ricaurte, D.J. Schretlen, U. McCann, J. Varga, and W.B. Mathews Positron emission tomography of striatal serotonin transporters in Parkinson's disease Arch Neurol 60 2003 1223 1229
28. K.A. Jellinger Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 56 1999 1 29
29. G.M. Halliday, Y.W. Li, P.C. Blumbergs, T.H. Joh, R.G. Cotton, and P.R. Howe Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease Ann Neurol 27 1990 373 385
30. R.B. Schiffer, R. Kurlan, A. Rubin, and S. Boer Evidence for atypical depression in Parkinson's disease Am J Psychiatry 145 1988 1020 1022
31. M.G. Weisskopf, H. Chen, M.A. Schwarzschild, I. Kawachi, and A. Ascherio Prospective study of phobic anxiety and risk of Parkinson's disease Mov Disord 18 2003 646 651
32. M. Shiba, J.H. Bower, D.M. Maraganore, S.K. McDonnell, B.J. Peterson, and J.E. Ahlskog Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study Mov Disord 15 2000 669 677
33. Diagnostic and statistical manual of mental disorders DSM-IV-TR Text revised 4th edition 2000 American Psychiatric Association Press Washington, DC
34. A.T. Beck, N. Epstein, G. Brown, and R.A. Steer An inventory for measuring clinical anxiety: psychometric properties J Consult Clin Psychol 56 1988 893 897
35. A.S. Zigmond, and R.P. Snaith The Hospital Anxiety and Depression Scale Acta Psychiatr Scand 67 1983 361 370
36. J. Marinus, A.F. Leentjens, M. Visser, A.M. Stiggelbout, and J.J. Van Hilten Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease Clin Neuropharmacol 25 2002 318 324
37. M.I. Tarczy, and E. Szombathelyi Depression in Parkinson's disease with special regard to anxiety: experiences with paroxetine treatment [abstract] Mov Disord 13 Suppl 2 1998 275
38. L.M. Shulman, C. Singer, R. Liefert, T. Mellman, and W.J. Weiner Therapeutic effects of sertraline in patients with Parkinson's disease [abstract] Mov Disord 11 1996 12
39. C.L. Ludwig, D.R. Weinberger, G. Bruno, M. Gillespie, K. Bakker, and P.A. LeWitt Buspirone, Parkinson's disease, and the locus ceruleus Clin Neuropharmacol 9 1986 373 378
40. M. Casacchia, A. Zamponi, G. Squitieri, and G. Meco Treatment of anxiety in Parkinson's disease with bromazepam [in Italian] Riv Neurol 45 1975 326 338
41. C. Chuang, and S. Fahn Dramatic benefit with clonazepam treatment of intractable anxiety and panic attacks in Parkinson's disease [abstract] Mov Disord 16 Suppl 1 2001 S35
42. R.G. Cumming, and D.G. Le Couteur Benzodiazepines and risk of hip fractures in older people: a review of the evidence CNS Drugs 17 2003 825 837
43. B.R. Bloem, Y.A. Grimbergen, M. Cramer, M. Willemsen, and A.H. Zwinderman Prospective assessment of falls in Parkinson's disease J Neurol 248 2001 950 958
44. L.D. Ried, R.E. Johnson, and D.A. Gettman Benzodiazepine exposure and functional status in older people J Am Geriatr Soc 46 1998 71 76
45. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco Buspirone in levodopa-induced dyskinesias Clin Neuropharmacol 17 1994 73 82
46. I.H. Richard, and R. Kurlan A survey of antidepressant drug use in Parkinson's disease Neurology 49 1997 1168 1170
47. Drug facts and comparisons 2004 Facts and Comparisons St. Louis (MO)
48. P.S. Masand, and S. Gupta Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine Ann Clin Psychiatry 14 2002 175 182
49. R.S. Gregorian, K.A. Golden, A. Bahce, C. Goodman, W.J. Kwong, and Z.M. Khan Antidepressant-induced sexual dysfunction Ann Pharmacother 36 2002 1577 1589
50. R.K. Shrivastava, S. Shrivastava, N. Overweg, and M. Schmitt Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors J Clin Psychopharmacol 15 1995 83 84
51. M. Gony, M. Lapeyre-Mestre, and J.L. Montastruc Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs Clin Neuropharmacol 26 2003 142 145
52. D.A. van de Vijver, R.A. Roos, P.A. Jansen, A.J. Porsius, and A. de Boer Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa Br J Clin Pharmacol 54 2002 168 170
53. G. Dell'Agnello, R. Ceravolo, A. Nuti, G. Bellini, A. Piccinni, and C. D'Avino SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study Clin Neuropharmacol 24 2001 221 227
54. E. Dzoljic, I. Kovacevic, M. Pokrajac, M. Mijalovic, M. Milosevic, and V. Kostic Plasma concentrations of fluoxetine and motor signs in patients with Parkinson's disease [abstract] Mov Disord 19 Suppl 9 2004 S235
55. K.A. Chung, and J.G. Nutt The effects of paroxetine on clinical response to levodopa in Parkinson's disease [abstract] Neurology 62 Suppl 5 2004 A331
56. I.H. Richard, R. Kurlan, C. Tanner, S. Factor, J. Hubble, and O. Suchowersky Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease Neurology 48 1997 1070 1077
57. Parkinson Study Group A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study Arch Neurol 59 2002 1937 1943
58. K. Black, C. Shea, S. Dursun, and S. Kutcher Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria J Psychiatry Neurosci 25 2000 255 261
59. J. Meara, E. Mitchelmore, and P. Hobson Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community Age Ageing 28 1999 35 38
60. E. Miller, G.E. Berrios, and B.E. Politynska Caring for someone with Parkinson's disease: factors that contribute to distress Int J Geriatr Psychiatry 11 1996 263 268
61. J.R. Slaughter, K.A. Slaughter, D. Nichols, S.E. Holmes, and M.P. Martens Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease J Neuropsychiatry Clin Neurosci 13 2001 187 196
62. A.F.G. Leentjens, J. Marinus, J.J. Van Hilten, R. Lousberg, and F.R.J. Verhey The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach J Neuropsychiatry Clin Neurosci 15 2003 74 77
63. D. Weintraub, P.J. Moberg, J.E. Duda, I.R. Katz, and M.B. Stern Recognition and treatment of depression in Parkinson's disease J Geriatr Psychiatry Neurol 16 2003 178 183
64. P. Naarding, A.F.G. Leentjens, F. van Kooten, and F.R.J. Verhey Disease-specific properties of the Hamilton Rating Scale for depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease J Neuropsychiatry Clin Neurosci 14 2002 329 334
65. A.F.G. Leentjens, F.R.J. Verhey, R. Lousberg, H. Spitsbergen, and F.W. Wilmink The validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as screening and diagnostic tools for depression in Parkinson's disease Int J Geriatr Psychiatry 15 2000 644 649
66. A. Rojo, M. Aguilar, M.T. Garolera, E. Cubo, I. Navas, and S. Quintana Depression in Parkinson's disease: clinical correlates and outcome Parkinsonism Relat Disord 10 2003 23 28
67. A.F. Leentjens, R. Lousberg, and F.R. Verhey Markers for depression in Parkinson's disease Acta Psychiatr Scand 106 2002 196 201
68. A. Schrag, M. Jahanshahi, and N.P. Quinn What contributes to depression in Parkinson's disease? Psychol Med 31 2001 65 73
69. A.M. Gotham, R.G. Brown, and C.D. Marsden Depression in Parkinson's disease: a quantitative and qualitative analysis J Neurol Neurosurg Psychiatry 49 1986 381 389
70. U. Merschdorf, D. Berg, I. Csoti, F. Fornadi, B. Merz, and M. Naumann Psychopathological symptoms of depression in Parkinson's disease compared to major depression Psychopathology 36 2003 221 225
71. G. Kuzis, L. Sabe, C. Tiberti, R. Leiguarda, and S. Starkstein Cognitive functions in major depression and Parkinson's disease Arch Neurol 54 1997 982 986
72. S.E. Starkstein, H.S. Mayberg, R. Leiguarda, T.J. Preziosi, and R.G. Robinson A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease J Neurol Neurosurg Psychiatry 55 1992 377 382
73. S.E. Starkstein, T.J. Preziosi, and R.G. Robinson Sleep disorders, pain, and depression in Parkinson's disease Eur Neurol 31 1991 352 355
74. S.E. Starkstein, P.L. Bolduc, H.S. Mayberg, T.J. Preziosi, and R.G. Robinson Cognitive impairments and depression in Parkinson's disease: a follow up study J Neurol Neurosurg Psychiatry 53 1990 597 602
75. S.A. Cole, J.L. Woodard, J.L. Juncos, J.L. Kogos, E.A. Youngstrom, and R.L. Watts Depression and disability in Parkinson's disease J Neuropsychiatry Clin Neurosci 8 1996 20 25
76. M. Welsh, L. Hung, and C.H. Waters Sexuality in women with Parkinson's disease Mov Disord 12 1997 923 927
77. R.G. Brown, M. Jahanshahi, N. Quinn, and C.D. Marsden Sexual function in patients with Parkinson's disease and their partners J Neurol Neurosurg Psychiatry 53 1990 480 486
78. D.J. Zgaljardic, J.C. Borod, N.S. Foldi, and P. Mattis A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry Cogn Behav Neurol 16 2003 193 210
79. T. Murai, U. Muller, K. Werheid, D. Sorger, M. Reuter, and T. Becker In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease J Neuropsychiatry Clin Neurosci 13 2001 222 228
80. H.S. Mayberg, S.E. Starkstein, B. Sadzot, T. Preziosi, P.L. Andrezejewski, and R.F. Dannals Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease Ann Neurol 28 1990 57 64
81. R. Mayeux, Y. Stern, L. Cote, and J.B. Williams Altered serotonin metabolism in depressed patients with Parkinson's disease Neurology 34 1984 642 646
82. W. Kuhn, T. Muller, M. Gerlach, E. Sofic, G. Fuchs, and N. Heye Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients J Neural Transm 103 1996 1441 1445
83. P.E. O'Suilleabhain, V. Sung, C. Hernandez, L. Lacritz, R.B. Dewey Jr., and T. Bottiglieri Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations Arch Neurol 61 2004 865 868
84. T.S. Ehmann, R.J. Beninger, M.J. Gawel, and R.J. Riopelle Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects J Geriatr Psychiatry Neurol 3 1990 3 9
85. A.F. Leentjens, M. Van den Akker, J.F. Metsemakers, R. Lousberg, and F.R. Verhey Higher incidence of depression preceding the onset of Parkinson's disease: a register study Mov Disord 18 2003 414 418
86. E.M. Cheng, A. Siderowf, K. Swarztrauber, M. Eisa, M. Lee, and B.G. Vickrey Development of quality of care indicators for Parkinson's disease Mov Disord 19 2004 136 150
87. S.E. Starkstein, T.J. Preziosi, A.W. Forrester, and R.G. Robinson Specificity of affective and autonomic symptoms of depression in Parkinson's disease J Neurol Neurosurg Psychiatry 53 1990 869 873
88. M.B. First, and M. Gibbon Structured clinical interview for DSM-IV axis I disorders (SCID-I), clinician version 1997 American Psychiatric Association Press Washington, DC
89. Robins LN, Cottler LB, Bucholz KK, Compton WM, North C, Rourke K. The Diagnostic Interview Schedule for DSM-IV (DIS-IV). St. Louis (MO): Washington University School of Medicine; revised, January 2000.
90. Composite International Diagnostic Interview, version 1.1 (CIDI researcher's manual) 1994 American Psychiatric Association Press Washington, DC
91. J. Williams A structured interview guide for the Hamilton Depression Rating Scale Arch Gen Psychiatry 45 1988 742 747
92. S.A. Montgomery, and M. Asberg A new depression scale, designed to be sensitive to change Br J Psychiatry 134 1979 382 389
93. M.P. Pignone, B.N. Gaynes, J.L. Rushton, C.M. Burchell, C.T. Orleans, and C.D. Mulrow Screening for depression in adults: a summary of the evidence for the US Preventive Services Task Force Ann Intern Med 136 2002 765 776
94. A. Beck, R. Steer, and G. Brown Manual for the Beck Depression Inventory 2nd edition 1996 Psychological Corporation San Antonio (TX)
95. J.A. Yesavage Geriatric depression scale Psychopharmacol Bull 24 1988 709 710
96. W. Zung A self-rating depression scale Arch Gen Psychiatry 12 1965 63 70
97. L. Radloff The CES-D scale: a self-report depression scale for research in the general population Appl Psychol Meas 1 1977 385 401
98. B.E. Levin, M.M. Llabre, and W.J. Weiner Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory J Neurol Neurosurg Psychiatry 51 1988 1401 1404
99. A.F. Leentjens, F.R. Verhey, G.J. Luijckx, and J. Troost The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease Mov Disord 15 2000 1221 1224
100. J.I. Sheikh, and J.A. Yesavage Geriatric Depression Scale (GDS): recent evidence and development of a shorter version T.L. Brink Clinical gerontology: a guide to assessment and intervention 1986 Haworth Press New York
101. S.M. Scheinthal, R.A. Steer, L. Giffin, and A.T. Beck Evaluating geriatric medical outpatients with the Beck Depression Inventory-Fast screen for medical patients Aging Ment Health 5 2001 143 148
102. M.S. Okun, B.L. Walter, W.M. McDonald, J.L. Tenover, J. Green, and J.L. Juncos Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson's disease Arch Neurol 59 2002 1750 1753
103. A. Antonini, A. Zecchinelli, S. Tesei, G. Saciloto, N. Meucci, and G. Pezzoli A randomized single-blind study of sertraline vs. amitriptyline for the treatment of depression in patients with Parkinson's disease Mov Disord 19 Suppl 9 2004 S263
104. F. Fregni, C.M. Santos, M.L. Myczkowski, R. Rigolino, J. Gallucci-Neto, and E.R. Barbosa Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease J Neurol Neurosurg Psychiatry 75 2004 1171 1174
105. R. Weiser, J. Hernandez-Rojas, J. Flores, M. Gallardo, M. Garcia, and M. Grau Efficacy, tolerability and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson's disease Mov Disord 19 Suppl 9 2004 S205
106. A. Avila, X. Cardona, M. Martin-Baranera, P. Maho, F. Sastre, and J. Bello Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial J Clin Psychopharmacol 23 2003 509 513
107. A.F.G. Leentjens, F.W. Vreeling, G.J. Luijckx, and F.R.J. Verhey SSRIs in the treatment of depression in Parkinson's disease Int J Geriatr Psychiatry 18 2003 552 554
108. M. Serrano-Duenas A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease Rev Neurol 35 2002 1010 1014 [in Spanish]
109. L. Wermuth, P.S. Sorensen, B. Timm, N.P. Utzon, J. Boas, and E. Dupont Depression in idiopathic Parkinson's disease treated with citalopram - a placebo-controlled trial Nord J Psychiatry 52 1998 163 169
110. J.M. Rabey, E. Orlov, and A.D. Korczyn Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease [abstract] Neurology 46 1996 A374
111. J. Anderson, E. Aabro, N. Gulmann, A. Hjelmsted, and H.E. Pederson Antidepressive treatment in Parkinson's disease - a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa Acta Neurol Scand 62 1980 210 219
112. L. Laitinen Desipramine in treatment of Parkinson's disease Acta Neurol Scand 45 1969 109 113
113. R.R. Strang Imipramine in treatment of Parkinson's disease: a double-blind placebo study Br Med J 452 1965 33 34
114. C.G. Goetz, W.C. Koller, W. Poewe, O. Rascol, and C. Sampaio Treatment of depression in idiopathic Parkinson's disease Mov Disord 17 Suppl 4 2002 S112 S119
115. D.D. Sa, S. Kapur, and A.E. Lang Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis Clin Neuropharmacol 24 2001 242 243
116. C.E. Coffey, D.R. Ross, E.W. Massey, and C.W. Olanow Dyskinesias associated with lithium therapy in parkinsonism Clin Neuropharmacol 7 1984 223 229
117. E. Spina, and M.G. Scordo Clinically significant drug interactions with antidepressants in the elderly Drugs Aging 19 2002 299 320
118. E. Richelson Pharmacokinetic interactions of antidepressants J Clin Psychiatry 59 Suppl 10 1998 22 26
119. A.J. Mandell, C. Markham, and W. Fowler Parkinson's syndrome, depression and imipramine: a preliminary report Calif Med 95 1961 12 14
120. H. Strauss Office treatment of depressive states with a new drug (imipramine) N Y State J Med 59 1959 2906 2910
121. H.S. Gill, C.L. DeVane, and S.C. Risch Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypothesis J Clin Psychopharmacol 17 1997 377 389
122. P. Vandel, B. Bonin, E. Leveque, D. Sechter, and P. Bizouard Tricyclic antidepressant-induced extrapyramidal side effects Eur Neuropsychopharmacol 7 1997 207 212
123. D. Weintraub, D. Taraborelli, J.E. Duda, P.J. Moberg, I.R. Katz, and M.B. Stern Escitalopram for the treatment of major depression in Parkinson's disease: impact on depression, cognition, and motor function Mov Disord 19 Suppl 9 2004 S188
124. L. Rampello, S. Chiechio, R. Raffaele, I. Vecchio, and F. Nicoletti The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa Clin Neuropharmacol 25 2002 21 24
125. J.L. Montastruc, N. Fabre, O. Blin, J.M. Senard, O. Rascol, and A. Rascol Does fluoxetine aggravate Parkinson's disease? A pilot prospective study Mov Disord 10 1995 355 357
126. R. Ceravolo, A. Nuti, A. Piccinni, G. Dell'Agnello, G. Bellini, and G. Gambaccini Paroxetine in Parkinson's disease: effects on motor and depressive symptoms Neurology 55 2000 1216 1218
127. S. Tesei, A. Antonini, M. Canesi, A. Zecchinelli, C.B. Mariani, and G. Pezzoli Tolerability of paroxetine in Parkinson's disease: a prospective study Mov Disord 15 2000 986 989
128. W. Wittgens, O. Donath, and U. Trenckmann Treatment of depressive syndromes in Parkinson's disease (P.D.) with paroxetine [abstract] Mov Disord 12 Suppl 1 1997 128
129. K. Bayulkem, and F. Torun Effectiveness of sertraline in treatment of depression with Parkinson's disease [abstract] Mov Disord 17 Suppl 5 2002 S74
130. R.A. Hauser, and T.A. Zesiewicz Sertraline for the treatment of depression in Parkinson's disease Mov Disord 12 1997 756 759
131. R.J. Meara, B.K. Bhowmick, and J.P. Hobson An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease J Serotonin Res 4 1996 243 249
132. A. Di Rocco, J.D. Rogers, R. Brown, P. Werner, and T. Bottiglieri S-adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial Mov Disord 15 2000 1225 1229
133. A.F. Leentjens, F.R. Verhey, and F.W. Vreeling Successful treatment of depression in a Parkinson disease patient with bupropion Ned Tijdschr Geneeskd 144 2000 2157 2159 [in Dutch]
134. P.H. Gordon, S.L. Pullman, E.D. Louis, S.J. Frucht, and S. Fahn Mirtazapine in parkinsonian tremor Parkinsonism Relat Disord 9 2002 125 126
135. G. Meco, E. Fabrizio, S. Di Rezze, A. Alessandri, and L. Pratesi Mirtazapine in L-dopa-induced dyskinesias Clin Neuropharmacol 26 2003 179 181
136. C. Normann, B. Hesslinger, M. Frauenknecht, M. Berger, and J. Walden Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine Pharmacopsychiatry 30 1997 263 265
137. M. Onofrj, A.L. Luciano, A. Thomas, D. Iacono, and G. D'Andreamatteo Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism Neurology 60 2003 113 115
138. G. Bagdy, M. Graf, Z.E. Anheuer, E.A. Modos, and S. Kantor Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635 Int J Neuropsychopharmacol 4 2001 399 408
139. K. Bayulkem, and F. Torun Therapeutic efficiency of venlafaxine in depressive patients with Parkinson's disease [abstract] Mov Disord 7 Suppl 5 2002 S75
140. H. Reichmann, M.H. Brecht, J. Koster, P.H. Kraus, and M.R. Lemke Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease CNS Drugs 17 2003 965 973
141. I. Rektorova, I. Rektor, M. Bares, V. Dostal, E. Ehler, and Z. Fanfrdlova Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study Eur J Neurol 10 2003 399 406
142. L. Lattanzi, L. Dell'Osso, P. Cassano, S. Pini, P. Rucci, and P.R. Houck Pramipexole in treatment-resistant depression: a 16-week naturalistic study Bipolar Disord 4 2002 307 314
143. M.H. Corrigan, A.Q. Denahan, C.E. Wright, R.J. Ragual, and D.L. Evans Comparison of pramipexole, fluoxetine, and placebo in patients with major depression Depress Anxiety 11 2000 58 65
144. C. Moellentine, T. Rummans, J.E. Ahlskog, W.S. Harmsen, V.J. Suman, and M.K. O'Connor Effectiveness of ECT in patients with parkinsonism J Neuropsychiatry Clin Neurosci 10 1998 187 193
145. N. Dragasevic, A. Potrebic, A. Damjanovic, E. Stefanova, and V.S. Kostic Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study Mov Disord 17 2002 528 532
146. M.D. Miller, C. Cornes, E. Frank, L. Ehrenpreis, R. Silberman, and M.A. Schlernitzauer Interpersonal psychotherapy for late-life depression: past, present, and future J Psychother Pract Res 10 2001 231 238
147. M.T. Pellecchia, A. Grasso, L.G. Biancardi, M. Squillante, V. Bonavita, and P. Barone Physical therapy in Parkinson's disease: an open long-term rehabilitation trial J Neurol 251 2004 595 598
148. M. Doraiswamy, W. Martin, A. Metz, and J. Deveaugh-Geiss Psychosis in Parkinson's disease: diagnosis and treatment Prog Neuropsychopharmacol Biol Psychiatry 19 1995 835 846
149. J. Barnes, and A.S. David Visual hallucinations in Parkinson's disease: a review and phenomenology survey J Neurol Neurosurg Psychiatry 70 2001 727 733
150. S. Holroyd, L. Currie, and G.F. Wooten Prospective study of hallucinations and delusions in Parkinsons's disease J Neurol Neurosurg Psychiatry 70 2001 734 738
151. R. Inzelberg, S. Kipervasser, and A.D. Korczyn Auditory hallucinations in Parkinson's disease J Neurol Neurosurg Psychiatry 64 1998 533 535
152. J.M. Graham, R.A. Grünewald, and H.J. Sagar Hallucinosis in idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 63 1997 434 440
153. J.R. Sanchez-Ramos, R. Ortoll, and G.W. Paulson Visual hallucinations associated with Parkinson's disease Arch Neurol 53 1996 1265 1268
154. D. Naimark, E. Jackson, E. Rockwell, and D.V. Jeste Psychotic symptoms in Parkinson's disease patients with dementia J Am Geriatr Soc 44 1996 296 299
155. S.A. Factor, P.J. Feustel, J.H. Friedman, C.L. Comella, C.G. Goetx, and R. Kurlan Longitudinal outcome of Parkinson's disease patients with psychosis Neurology 60 2003 1756 1761
156. S.A. Factor, E.S. Molho, G.D. Podskalny, and D. Brown Parkinson's disease: drug-induced psychiatric states Adv Neurol 65 1995 115 138
157. Y. de Smet, M. Ruberg, M. Serdaru, B. Dubois, F. Lhermitte, and Y. Agid Confusion, dementia, and anticholinergics in Parkinson's disease J Neurol Neurosurg Psychiatry 45 1982 1161 1164
158. C. Moskovitz, H. Moses, and H.L. Klawans Levodopa-induced psychosis: a kindling phenomenon Am J Psychiatry 135 1978 669 675
159. C.G. Goetz, E.J. Pappert, L.M. Blasucci, G.T. Stebbins, Z.D. Ling, and M.V. Nora Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations Neurology 50 1998 515 517
160. D. Aarsland, C. Ballard, J.P. Larsen, and I. McKeith A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia Int J Geriatr Psychiatry 16 2001 528 536
161. I. Arnulf, A.-M Bonnet, P. Damier, B.-P Bejjani, D. Seilhean, and J.-P Derenne Hallucinations, REM sleep, and Parkinson's disease Neurology 55 2000 281 288
162. T. Nomura, Y. Inoue, H. Mitani, R. Kawahara, M. Miyake, and K. Nakasima Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease Mov Disord 18 2003 812 817
163. Y. Abe, T. Kachi, T. Kato, Y. Arahata, T. Yamada, and Y. Washimi Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing J Neurol Neurosurg Psychiatry 74 2003 419 422
164. N.J. Diederich, C.G. Goetz, R. Raman, E.J. Pappert, S. Leurgans, and V. Piery Poor visual discrimination and visual hallucinations in Parkinson's disease Clin Neuropharmacol 21 1998 289 295
165. T. Vander Borght, S. Minoshima, B. Giordani, N.L. Foster, K.A. Frey, and S. Berent Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity J Nucl Med 38 1997 797 802
166. T. Buttner, W. Kuhn, T. Muller, T. Patzold, K. Heidbrink, and H. Przuntek Distorted color discrimination in "de novo" parkinsonian patients Neurology 45 1995 376 377
167. I. Bodis-Wollner Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients Trends Neurosci 13 1990 296 302
168. J.J. Downes, A.C. Robert, B.J. Sahakian, J.L. Evenden, R.G. Morris, and T.W. Robbins Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction Neuropsychologia 27 1989 1329 1349
169. J. Wang, C. Zhao, B. Chen, and Z.L. Liu Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease Neurosci Lett 355 2004 193 196
170. C.G. Goetz, P.F. Burke, S. Leurgans, E. Berry-Kravis, L.M. Blasucci, and R. Raman Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study Arch Neurol 58 2001 209 213
171. A.J. Makoff, J.M. Graham, M.J. Arranz, J. Forsyth, T. Li, and K.J. Aitchison Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease Pharmacogenetics 10 2000 43 48
172. G. Friedberg, J. Zoldan, A. Weizman, and E. Melamed Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease Clin Neuropharmacol 21 1998 280 284
173. I. McKeith, J. Mintzer, D. Aarsland, D. Burn, H. Chiu, and J. Cohen-Mansfield Dementia with Lewy bodies Lancet Neurol 3 2004 19 28
174. V. Biousse, B.C. Skibell, R.L. Watts, D.N. Loupe, C. Drews-Botsch, and N.J. Newman Ophthalmologic features of Parkinson's disease Neurology 62 2004 177 180
175. N.J. Diederich, V. Pieri, and C.G. Goetz Coping strategies for visual hallucinations in Parkinson's disease Mov Disord 18 2003 831 838
176. H.H. Fernandez, M.E. Trieschmann, and M.S. Okun Discontinuation of antipsychotic drugs in stable Parkinson patients with a history of drug-induced psychosis Mov Disord 19 Suppl 9 2004 S400
177. P. Pollak, F. Tison, O. Rascol, A. Destee, J.J. Pere, and J.M. Senard Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up J Neurol Neurosurg Psychiatry 75 2004 689 695
178. French Parkinson Study Group Clozapine in drug-induced psychosis in Parkinson's disease Lancet 353 1999 2041 2042
179. Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease N Engl J Med 340 1999 757 763
180. J.H. Friedman, and S.A. Factor Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease Mov Disord 15 2000 201 211
181. J.H. Friedman, and M.C. Lannon Benztropine versus clozapine for the treatment of tremor in Parkinson's disease Neurology 4 1997 1077 1081
182. F. Durif, B. Debilly, M. Galitzky, D. Morand, F. Viallet, and M. Borg Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study Neurology 62 2004 381 388
183. C. Klein, J. Gordon, L. Pollak, and J.M. Rabey Clozapine in Parkinson's disease psychosis: 5-year follow-up review Clin Neuropharmacol 26 2003 8 11
184. H.H. Fernandez, M.E. Trieschmann, and J.H. Friedman Treatment of
185. J. Rudolf, M. Grond, M. Neveling, and W.D. Heiss Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis J Neural Transm 104 1997 1305 1311
186. J.G. Killian, K. Kerr, C. Lawrence, and D.S. Celermajer Myocarditis and cardiomyopathy associated with clozapine Lancet 354 1999 1841 1845
187. F. Mancini, C. Tassorelli, E. Martignoni, A. Moglia, G. Nappi, and S. Cristina Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease Clin Neuropharmacol 27 2004 33 37
188. J.L. Juncos, V.J. Roberts, M.L. Evatt, R.D. Jewart, C.D. Wood, and L.S. Potter Quetiapine improves psychotic symptoms and cognition in Parkinson's disease Mov Disord 19 2004 29 35
189. H.H. Fernandez, M.E. Trieschmann, M.A. Burke, C. Jacques, and J.H. Friedman Long-term outcome of quetiapine use for psychosis among parkinsonian patients Mov Disord 18 2003 510 514
190. H.H. Fernandez, M.E. Trieschmann, M.A. Burke, and J.H. Friedman Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies J Clin Psychiatry 63 2002 513 515
191. S. Reddy, S.A. Factor, E.S. Molho, and P.J. Feustel The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia Mov Disord 17 2002 676 681
192. L. Morgante, A. Epifanio, E. Spina, A.E. Di Rosa, M. Zappia, and G. Basile Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease Neurol Sci 23 Suppl 2 2002 S89 S90
193. R.B. Dewey Jr., and P.E. O'Suilleabhain Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease Neurology 55 2000 1753 1754
194. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Drug-induced psychosis in parkinsonian syndromes: predictors of non-response. Presented at the 15th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson's disease and Other Movement Disorders. Chicago, September 30, 2001.
195. M.E. Trieschmann, H.H. Fernandez, and J.H. Friedman New-onset diabetes in parkinsonian patients on long-term quetiapine [abstract] Mov Disord 18 2003 1095
196. R. Katzenschlager, A.J. Manson, A. Evans, H. Watt, and A.J. Lees Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study J Neurol Neurosurg Psychiatry 75 2004 295 297
197. M.S. Baron, and W.B. Dalton Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease Mov Disord 18 2003 1208 1209
198. N. Leopold Risperidone treatment of drug-related psychosis in patients with parkinsonism Mov Disord 15 2000 301 304
199. G. Meco, A. Alessandri, P. Guistini, and V. Bonifati Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open label long term study Mov Disord 12 1997 610 612
200. S.S. Rich, J.H. Friedman, and B.R. Ott Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes J Clin Psychiatry 56 1995 556 559
201. B. Ford, T. Lynch, and P. Greene Risperidone in Parkinson's disease [letter] Lancet 344 1994 681
202. S.A. Factor, E.S. Mohlo, and J.H. Friedman Risperidone and Parkinson's disease Mov Disord 17 2001 221 225
203. T. Ellis, M.E. Cudkowicz, P.M. Sexton, and J.H. Growdon Clozapine and risperidone treatment of psychosis in Parkinson's disease J Clin Neurosci 12 2000 364 369
204. A. Breier, V.K. Sutton, P.D. Feldman, D.L. Kadam, I. Ferchland, and P. Wright Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease Biol Psychiatry 52 2002 438 445
205. W.G. Ondo, J.K. Levy, K.D. Vuong, C. Hunter, and J. Jankovic Olanzapine treatment for dopaminergic-induced hallucinations Mov Disord 17 2002 1031 1035
206. C.G. Goetz, L.M. Blasucci, S. Leurgans, and E.J. Pappert Olanzapine and clozapine. Comparative effects on motor functioning in hallucinating PD patients Neurology 55 2000 748 749
207. S. Gimenez-Roldan, D. Mateo, E. Navarro, and M.M. Gines Efficacy and safety of clozapine and olanzapine: an open label trial comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis Parkinsonism Relat Disord 7 2001 121 127
208. L. Marsh, C. Lyketsos, and S.G. Reich Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia Psychosomatics 42 2001 477 481
209. D. Aarsland, J.P. Larsen, N.G. Lim, and E. Tandberg Olanzapine for psychosis in patients with Parkinson's disease with and without dementia J Neuropsychiatry Clin Neurosci 11 1999 392 394
210. E.S. Molho, and S.A. Factor Worsening of motor features of parkinsonism with olanzapine Mov Disord 14 1999 1014 1016
211. H.H. Fernandez, M.E. Trieschmann, and J.H. Friedman Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience Clin Neuropharmacol 27 2004 4 5
212. M. Oechsner, and A. Korchounov Parenteral treatment of acute psychosis in Parkinson's disease with ziprasidone Mov Disord 19 Suppl 9 2004 S213
213. B.J. Connemann, and C. Schonfeldt-Lecona Ziprasidone in Parkinson's disease psychosis [letter] Can J Psychiatry 49 2004 73
214. S.A. Factor, E.S. Molho, and D.L. Brown Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease J Neuropsychiatry Clin Neurosci 7 1995 304 307
215. T. Huritz, D. Calne, and K. Waterman Treatment of dopamimetic psychosis in Parkinson's disease with electroconvulsive therapy Can J Neurol Sci 15 1988 32 34
216. R. Douyon, M. Serby, B. Klutcho, and J. Rotrosen ECT and Parkinson's disease revisited: a naturalistic study Am J Psychiatry 146 1989 1451 1455
217. D. Aarsland, M. Hutchinson, and J.P. Larsen Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia Int J Geriatr Psychiatry 18 2003 937 941
218. J. Bergman, and V. Lerner Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease Clin Neuropharmacol 22 2002 107 110
219. R. Bullock, and A. Cameron Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series Curr Med Res Opin 18 2002 258 264
220. G. Fabbrini, P. Barbanti, C. Aurilia, C. Pauletti, G.L. Lenzi, and G. Meco Donepezil in the treatment of hallucinations and delusions in Parkinson's disease Neurol Sci 23 2002 41 43
221. P.J. Reading, A.K. Luce, and I.G. McKeith Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary finding from an open trial Mov Disord 16 2001 1171 1195
222. T.E. Eichhorn, E. Brunt, and W.H. Oertel Ondansetron treatment of L-dopa-induced psychosis Neurology 47 1996 1608 1609
223. J. Zoldan, G. Friedberg, M. Livneh, and E. Melamed Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist Neurology 45 1995 1305 1308
224. D.M. Weiner, K.E. Vanover, M.R. Brann, H.Y. Meltzer, and R.E. Davis Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics Curr Opin Investig Drugs 4 2003 815 819